Compare IMXI & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | EOLS |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 407.0M |
| IPO Year | 2016 | 2018 |
| Metric | IMXI | EOLS |
|---|---|---|
| Price | $14.99 | $6.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $15.00 | ★ $15.50 |
| AVG Volume (30 Days) | 446.4K | ★ 672.7K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $319,601,000.00 | $297,176,000.00 |
| Revenue This Year | $0.83 | $13.27 |
| Revenue Next Year | $1.49 | $17.62 |
| P/E Ratio | $744.00 | ★ N/A |
| Revenue Growth | ★ 16.68 | 11.61 |
| 52 Week Low | $8.58 | $3.86 |
| 52 Week High | $15.95 | $10.20 |
| Indicator | IMXI | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 60.19 |
| Support Level | $14.86 | $5.95 |
| Resistance Level | $15.19 | $7.29 |
| Average True Range (ATR) | 0.23 | 0.36 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 52.86 | 82.32 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.